821 related articles for article (PubMed ID: 28869450)
41. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
[TBL] [Abstract][Full Text] [Related]
42. [The expression of IDH1 (R132H) is positively correlated with cell proliferation and angiogenesis in glioma samples].
Shi J; Zhao Y; Yuan Y; Wang C; Xie Z; Gao X; Xiao L; Ye J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):360-3. PubMed ID: 26927556
[TBL] [Abstract][Full Text] [Related]
43. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
[TBL] [Abstract][Full Text] [Related]
44. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
Yu J; Shi Z; Lian Y; Li Z; Liu T; Gao Y; Wang Y; Chen L; Mao Y
Eur Radiol; 2017 Aug; 27(8):3509-3522. PubMed ID: 28004160
[TBL] [Abstract][Full Text] [Related]
45. Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
Kim D; Kim S; Kim SH; Chang JH; Yun M
Clin Nucl Med; 2018 May; 43(5):311-316. PubMed ID: 29485450
[TBL] [Abstract][Full Text] [Related]
46. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.
Cai J; Zhu P; Zhang C; Li Q; Wang Z; Li G; Wang G; Yang P; Li J; Han B; Jiang C; Sun Y; Jiang T
Oncotarget; 2016 Mar; 7(13):16384-95. PubMed ID: 26918938
[TBL] [Abstract][Full Text] [Related]
47. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
[TBL] [Abstract][Full Text] [Related]
49. Histone H3.3 G34-mutant Diffuse Gliomas in Adults.
Wang L; Shao L; Li H; Yao K; Duan Z; Zhi C; Song S; Cheng Y; Wang F; Wang W; Piao Y; Gui Q; Lu D; Qi X; Teng L
Am J Surg Pathol; 2022 Feb; 46(2):249-257. PubMed ID: 34352809
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
[TBL] [Abstract][Full Text] [Related]
51. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
Gozé C; Blonski M; Le Maistre G; Bauchet L; Dezamis E; Page P; Varlet P; Capelle L; Devaux B; Taillandier L; Duffau H; Pallud J
Neuro Oncol; 2014 Aug; 16(8):1100-9. PubMed ID: 24847087
[TBL] [Abstract][Full Text] [Related]
52. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
Ohno M; Narita Y; Miyakita Y; Okita Y; Matsushita Y; Yoshida A; Fukushima S; Ichimura K; Kayama T; Shibui S
Brain Tumor Pathol; 2012 Oct; 29(4):183-91. PubMed ID: 22790483
[TBL] [Abstract][Full Text] [Related]
53. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
[TBL] [Abstract][Full Text] [Related]
54. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
55. H3F3A K27M mutations in thalamic gliomas from young adult patients.
Aihara K; Mukasa A; Gotoh K; Saito K; Nagae G; Tsuji S; Tatsuno K; Yamamoto S; Takayanagi S; Narita Y; Shibui S; Aburatani H; Saito N
Neuro Oncol; 2014 Jan; 16(1):140-6. PubMed ID: 24285547
[TBL] [Abstract][Full Text] [Related]
56. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I
Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036
[TBL] [Abstract][Full Text] [Related]
57. Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.
Azar S; Leventoux N; Ripoll C; Rigau V; Gozé C; Lorcy F; Bauchet L; Duffau H; Guichet PO; Rothhut B; Hugnot JP
Glia; 2018 Feb; 66(2):239-255. PubMed ID: 29027701
[TBL] [Abstract][Full Text] [Related]
58. Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.
Phan K; Ng W; Lu VM; McDonald KL; Fairhall J; Reddy R; Wilson P
World Neurosurg; 2018 Mar; 111():e539-e545. PubMed ID: 29288860
[TBL] [Abstract][Full Text] [Related]
59. Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe.
Kurimoto M; Suzuki H; Aoki K; Ohka F; Kondo G; Motomura K; Iijima K; Yamamichi A; Ranjit M; Wakabayashi T; Kimura S; Natsume A
Cancer Invest; 2016; 34(1):12-5. PubMed ID: 26695622
[TBL] [Abstract][Full Text] [Related]
60. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]